Kollagenosen

Schlüsselwörter

Lupus erythematodes - systemische Sklerose - Dermatomyositis

Keywords

lupus erythematosus - systemic sclerosis - dermatomyositis

• Literatur

• 1 Amato AA, Tawil R, Kissel J et al. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 2011; 70: 427-436
• 2 Aringer M, Burkhardt H, Burmester GR et al. Current state of evidence on "off label" therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria, and Switzerland – a consensus report. Lupus 2011; Nov 9. [Epub ahead of print]
• 3 Bader-Meunier B, Decaluwe H, Barnerias C et al. Club Rhumatismes et Inflammation. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. Rheumatol 2011; 38: 1436-1440
• 4 Burt RK, Shah SJ, Dill K et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378: 498-506
• 5 Carrion FA, Figueroa FE. Mesenchymal stem cells for the treatment of systemic lupus erythematosus: is the cure for connective tissue diseases within connective tissue?. Stem Cell Res Ther 2011; 2: 23
• 6 Daoussis D, Liossis SN, Yiannopoulos G et al. B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence. Int J Rheumatol 2011; 2011: 214013, Epub 2011 Aug 3
• 7 Díaz-Lagares C, Croca S, Sangle S et al. The UK-BIOGEAS Registry. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. Autoimmun Rev 2011; Oct 18. [Epub ahead of print]
• 8 Dooley MA, Jayne D, Ginzler EM. ALMS Group et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. New Engl J Med 2011; 365: 1886-1895
• 9 Keyszer G, Christopeit M, Fick S et al. Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases. Arthritis Rheum 2011; 63: 2540-2542
• 10 Khanna D, Saggar R, Mayes MD et al. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum 2011; 63: 3540-3546
• 11 Le EN, Wigley FM, Shah AA et al. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2011; 70: 1104-1107
• 12 Navarra SV, Guzmán RM, Gallacher AE. BLISS-52 Study Group et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-731
• 13 Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep 2011; 13: 77-80
• 14 Pope J, McBain D, Petrlich L et al. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum 2011; 63: 3547-3551
• 15 Rovin BH, Furie R, Latinis K et al. for the LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab (LUNAR) study. Arthritis Rheum 2012; Jan 9. doi: [Epub ahead of print]
• 16 Wang D, Zhang H, Cao M et al. Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis. Ann Rheum Dis 2011; 70: 1285-1288